NYSE: BIO

Bio-Rad Laboratories (BIO) Stock Analysis & Forecast

Nov 13 close

$366.36−4.12 (−1.1%)

Gekko Brief

AI summaryNov 9 close

Bio-Rad's week centers on its Q3 2026 results, reported 4 November. Revenue came in at roughly $656 million, up 0.5% reported and 0.7% currency-neutral, marking the company's first currency-neutral growth quarter of 2026. Clinical Diagnostics rose 2.7% and returned to growth, Life Science dipped 2.8% overall but grew 2.5% excluding Process Chromatography, and ddPCR instrument revenue grew more than 20% for a third straight quarter. Non-GAAP gross margin expanded to 54.5%, EPS of $2.65 topped the $2.23 estimate, and full-year sales guidance was affirmed at $2.51 billion to $2.60 billion. The stock's reaction to the print was muted, down 1.6%.

Shares closed at $388.31, up 1.8%, and sit above both the 50-day average of $373.63 and the 200-day average of $315.40, with the shorter average above the longer one. The GekkoIndex reads 50.9, placing it in the Neutral zone, though the index has slipped 6.6 points over five days. Price sits 8.4% above Gekko Fair Value of $358.17.

The next earnings date falls on 11 February 2027, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the respective windows, and a single tracked analyst holds a buy rating with a $335 consensus target, implying downside of 13.7% from current levels. Seasonality from this point has averaged -0.3% over the next 20 trading days across five years, rising in four of them, a mixed historical pattern worth noting alongside the current stretch above both moving averages.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Bio-Rad Laboratories price vs fair value

$366.44$366.36Nov ’25May ’26Nov ’26
Close $366.36200-day averageGekko Fair Value $366.44

Bio-Rad Laboratories quick facts

Market cap
$9.85B
P/E ratio
10.3
Forward P/E
40.3
EPS, TTM
$36.13
Revenue, TTM
$2.59B
Profit margin
39.5%
Dividend yield
—
Beta
1.06
Volume
255,113 avg 256,267
1-year return
+11.9%
Typical daily move
±3.8%
Typical 20-day move
±5.6%
50-day average
$372.95
200-day average
$316.99
Next earnings
Feb 11 after close
Shares outstanding
21.83M
52-week range
$236.73$396.23

Bio-Rad Laboratories swing-trade checklist

Bio-Rad Laboratories scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed1 headwind

  • Trendmixed

    Averages disagree

    Close $366.36 sits between the 50-day ($372.95) and 200-day ($316.99) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    60, Accumulation

    Reading 60 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuemixed

    0.0% above

    Price is within 5% of Gekko Fair Value (0% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 88 days

    Next report Feb 11, 2027, 88 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −1.3% on average

    From this point in the calendar, the next 20 trading days averaged −1.3% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Bio-Rad Laboratories stock chart and price history

Bio-Rad Laboratories closed at $366.36 on Nov 13, 2026, +11.9% over the past year, inside a 52-week range of $236.73 to $396.23.

Close50-day average200-day averageVolume
Bio-Rad Laboratories share price, past year, with 50-day and 200-day moving averages and volume$250$300$350DecJan 2026FebMarAprMayJunJulAugSepOctNov366.36

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+0.4%
3 months
+3.1%
6 months
+48.0%
1 year
+11.9%
The full BIO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BIO in Gekko

Follow Bio-Rad Laboratories through every session

Put BIO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track BIO in GekkoFree for 7 days. No credit card required.

About Bio-Rad Laboratories

Bio-Rad Laboratories makes and sells equipment, reagents, and testing systems used in life science research and clinical diagnostics. Its work includes tools for separating and analyzing chemical and biological materials, and it is known for supplying laboratories with both instruments and the diagnostic kits that go with them. Customers reach the company across the United States, Canada, Europe, Asia, and Latin America.

The business runs through two divisions. The Life Science division builds reagents, instruments, and lab equipment for work in proteomics, genomics, biopharmaceutical manufacturing, cellular biology, and food safety, selling to universities, medical schools, government and industrial research bodies, pharmaceutical and biotech firms, and food producers and testing labs. The Clinical Diagnostics division supplies test systems, diagnostic kits, informatics tools, and quality control products for niche areas of in vitro diagnostics, serving reference and hospital laboratories, newborn screening centers, physicians' offices, and transfusion labs. Products reach customers through a direct sales force alongside distributors, agents, brokers, and resellers.

Bio-Rad Laboratories was founded in 1952 and is based in Hercules, California. Its shares are listed on the NYSE under the ticker BIO.

Listed
NYSE
Sector
Health technology
Industry
Medical specialties
Website
bio-rad.com

Bio-Rad Laboratories GekkoIndex: the smart money zone

Bio-Rad Laboratories’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60, in the Accumulation zone, up 5.6 points over five sessions.

010060Accumulation

Up 5.6 points over five sessions, from the Neutral zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying41−1.0%−0.5%−0.6%−2.7%
Accumulation (current zone)207+1.2%+1.4%+2.8%+3.6%
Neutral408+0.1%+0.4%+0.1%+2.3%
Distribution44−1.2%−1.6%+0.2%−2.7%
Selling2Too few readings yet

Average BIO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the BIO price, zone by zone.Track BIO in Gekko

Is Bio-Rad Laboratories stock overvalued? Gekko Fair Value

Bio-Rad Laboratories trades level with Gekko Fair Value of $366.44, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Bio-Rad Laboratories shares are worth, recalculated every trading day.

$366.44

Gekko Fair Value, Nov 14, 2026

0.0% from fair value · About fair value

At the end of Aug 2026 the price was 17.5% above the estimate.

Gekko Fair ValueShare price, month end
$366$366Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open BIO in Gekko

Bio-Rad Laboratories insider and Congress trading

No open-market insider purchases were filed for Bio-Rad Laboratories, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for BIO in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every BIO insider filing, plotted on the chart in Gekko.Open BIO in Gekko

Congress trades last 90 days

No trades in BIO were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for BIO, plotted on the chart in Gekko.Open BIO in Gekko

Buybacks

Bio-Rad Laboratories has been buying back its own shares.

Bought back, quarter ended Jun 30, 2026
$31.50M
As a share of market cap
0.32%

From company filings.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds BIO.

0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Bio-Rad Laboratories earnings: next date and track record

Bio-Rad Laboratories reports on Feb 11, 2027, after the close (88 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±7.6%average move across the report
2 of 8reports followed by a gain

Share-price move across each report

−11.3%Feb ’25−3.2%May ’25+13.8%Jul ’25−7.8%Oct ’25−12.6%Feb ’26−6.8%Apr ’26+3.9%Aug ’26−1.6%Nov ’26

Last earnings call, Nov 4, 2026 AI summary

What they said
Bio-Rad reported Q3 2026 revenue of ~$656 million, up 0.5% reported and 0.7% currency-neutral, marking their first quarter of currency-neutral growth in 2026. Non-GAAP gross margin expanded to 54.5%. ddPCR instrument revenue grew 20%+ for the third consecutive quarter, Life Science ex-Process Chromatography grew 2.5% YoY, and Clinical Diagnostics returned to growth. China returned to growth in APAC, though U.S. academic/government markets remain pressured with NIH outlays down ~15%.
Guidance
Q4 outlook does not assume recovery in academic/government markets. Process Chromatography expects sequential Q4 decline but full-year 2026 improvement YoY. Consumable pull-through normalization may extend into 2027. PAMA reimbursement changes expected to have limited indirect business impact.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 4, 2026$2.65
est $2.23
+18.8%$656.4M
est $649.9M
+1.0%−1.6%
Aug 4, 2026$2.62
est $1.75
+49.7%$651.0M
est $624.0M
+4.3%+3.9%
Apr 30, 2026$1.89
est $1.97
−4.1%$592.1M
est $589.9M
+0.4%−6.8%
Feb 12, 2026$2.51
est $2.57
−2.3%$693.2M
est $688.8M
+0.6%−12.6%
Oct 29, 2025$2.26
est $2.30
−1.7%$653.0M
est $694.6M
−6.0%−7.8%
Jul 31, 2025$2.61
est $1.93
+35.2%$651.6M
est $633.8M
+2.8%+13.8%
May 1, 2025$2.54
est $1.73
+46.8%$585.4M
est $573.2M
+2.1%−3.2%
Feb 13, 2025$2.90
est $2.88
+0.7%$667.5M
est $679.8M
−1.8%−11.3%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Bio-Rad Laboratories stock forecast and analyst price targets

Analysts’ average 12-month price target for Bio-Rad Laboratories is $356.67, −2.6% from the last close, from 1 firm rating the stock in the last 90 days.

$356.67consensus 12-month target, −2.6% from the last close
Buy1
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 1 firm.

Latest analyst actions

DateFirmRatingTargetvs price
Sep 27RBC CapitalBuy, maintained$390+6.5%
+2.8%average 20-day move after past Accumulation readings
−1.3%average move over the next 20 trading days in the last 5 years
±3.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Bio-Rad Laboratories seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Bio-Rad Laboratories averaged −1.3% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−4.0%2021+3.1%2022+2.2%2023−4.0%2024−1.7%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−3.1%2 of 5
Next 10 trading days−2.1%1 of 5
Next 15 trading days−3.4%1 of 5
Next 20 trading days−1.3%2 of 5
Next 30 trading days−1.9%1 of 5

For scale, BIO’s typical 20-trading-day move in either direction is about 5.6%.

Bio-Rad Laboratories market cap and key statistics

Bio-Rad Laboratories’s market cap is $9.85B, with a P/E ratio of 10.3 and revenue of $2.59B over the last twelve months.

Valuation

Market cap
$9.85B
P/E ratio
10.3
Forward P/E
40.3
EPS, TTM
$36.13
Gekko Fair Value
$366.44

Trading

Volume
255,113
Avg volume, 20 days
256,267
52-week high
$396.23
52-week low
$236.73
Shares outstanding
21.83M

Financials

Revenue, TTM
$2.59B
Profit margin
39.5%
Return on equity
14.3%
Quarterly earnings growth, YoY
+18.7%

Risk and income

Beta
1.06
Typical daily move
±3.8%
Typical 20-day move
±5.6%

Bio-Rad Laboratories peers

Bio-Rad Laboratories’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Bio-Rad Laboratories stock FAQ

What is Bio-Rad Laboratories’s market cap?

Bio-Rad Laboratories’s market cap is $9.85B at the Nov 13, 2026 close of $366.36, with 21.83M shares outstanding. The shares trade on a P/E ratio of 10.3.

What is the Bio-Rad Laboratories stock forecast?

The consensus analyst 12-month price target for Bio-Rad Laboratories is $356.67, −2.6% from the last close. Of the 1 firm that rated the stock in the last 90 days, 1 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Bio-Rad Laboratories stock overvalued or undervalued?

On Gekko’s estimate Bio-Rad Laboratories is about fair value: the Nov 13, 2026 close of $366.36 is level with Gekko Fair Value of $366.44. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Bio-Rad Laboratories report earnings next?

Bio-Rad Laboratories is expected to report on Feb 11, 2027, after the market closes (88 days away). Analysts expect earnings of $2.83 per share on revenue of $688.7M. Bio-Rad Laboratories beat the earnings estimate in 5 of its last 8 reports, moving 7.6% on average across the report.

What is Bio-Rad Laboratories’s 52-week high and low?

Bio-Rad Laboratories’s 52-week high is $396.23 and its 52-week low is $236.73; it closed at $366.36 on Nov 13, 2026, +11.9% over the past year. Over the last five years the shares peaked at $784.39 on Nov 17, 2021.

Is Bio-Rad Laboratories stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and earnings risk), 2 as mixed (trend and fair value) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Bio-Rad Laboratories the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.